SemBioSys Genetics granted immunoglobulin related patent

SemBioSys Genetics has announced it has been granted U.S. patent 7,098,383 entitled "Methods for the production of multimeric immunoglobulins, and related compositions".

The claims of the patent are directed to the production of antibodies in association with oilbodies.

"Antibodies are becoming an increasingly important form of therapeutics. The technology protected by this patent opens up new product opportunities for SemBioSys in the production of antibodies and other complex proteins. We believe our oilbody-oleosin technology is an efficient method for antibody production and recovery with substantial savings in both capital and cost-of-goods," said Andrew Baum, President and CEO of SemBioSys. "This patent demonstrates our commitment to protect our proprietary oilbody-oleosin technology and further strengthens our industry leading position for the production of proteins in plants."

In addition to the current patent, SemBioSys was also issued another U.S. patent 7,091,401 entitled "Expression of Epidermal Growth Factor (EGF) in plant seeds" on August 15, 2006, which covers chimeric nucleic acid sequences and methods of expression of EGF in plants and plant seeds. EGF is a human cytokine that has been shown to be important in many cellular regeneration processes including the proliferation of nerve and brain cells.

http://www.sembiosys.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rare variant analysis reveals genetic spectrum of monogenic diabetes genes